Liberty Health Sciences closes US $22M private placement

Liberty Health Sciences Announces USD $12 Million Private Placement Financing

Proceeds to finance expansion of Florida operation and increase production and growing space

Toronto, ON; November 22, 2017 – Liberty Health Sciences Inc. (CSE: LHS) (OTCBB: LHSIF) (“Liberty” or the “Company”) is pleased to announce the closing of a private placement offering of convertible secured debentures (“Notes”) for gross proceeds of USD $12 million. Pursuant to the Offering, the Company’s wholly-owned subsidiary Liberty Health Sciences Florida Ltd. sold USD $12 million aggregate principal amount of Notes at a face value of USD $1,000 per Note. The Notes bear interest of 12 per cent, payable semi-annually, and mature on November 22, 2020.

“This important financing deal will fund the aggressive expansion plan that we have in place that will see Liberty become one of the largest licensed producers in the State of Florida.” said George Scorsis, CEO and Director of Liberty. “As more and more physicians and patients see the tremendous value in cannabis as a viable treatment option, we continue to see immense growth in demand for high quality, clean and safe medical cannabis throughout the state. Aggressively expanding our operation allows us to serve even more patients in need.”

The Notes are secured by the assets of Liberty Health Sciences Florida Ltd. including a first priority general security agreement covering all present and future assets of the Florida business and a mortgage over all material real property of Liberty Health Sciences Florida Ltd.

Each USD $1,000 face value of the Notes is convertible at maturity into that number of common shares of Liberty which represents a conversion price of CAD $2.00 per common share unit. The Company has the right to redeem the Notes at a premium to principal in whole or in part at any time prior to maturity, and the Company has a right to force conversion of the Notes into common shares of Liberty at par plus accrued and unpaid interest if the common shares trade at or above CAD$3.00 for ten consecutive trading days, on a volume weighted average basis

For more information on Liberty, please visit www.libertyhealthsciences.com

About Liberty Health Sciences Inc.

Liberty Health Sciences Inc. (“Liberty”) is an investor and operator in the medical cannabis market, capitalizing on new and existing opportunities in U.S. states where medical cannabis is legal. Liberty’s stringent investment criteria for expansion maximizes returns to shareholders, while focusing on significant near and mid-term opportunities. Liberty has an extensive background in highly regulated industries, with expertise in becoming a low-cost producer. Liberty leverages commercial greenhouse knowledge to deliver high-quality, clean and safe pharmaceutical grade cannabis to patients.

For media inquiries, please contact:
Matt Salvatore
Edelman matt.salvatore@edelman.com
613.315.7362